---
schema_version: "secwatch.filing_event.v1"
accession: "0000885725-24-000003"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:47:31.283290+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Boston Scientific to acquire Axonics for $3.7B, expanding urology portfolio into sacral neuromodulation

## Summary
- Purchase price of $71 per share cash; equity value ~$3.7B, enterprise value ~$3.4B.
- Axonics 2023 revenue ~$366M (+34% YoY); deal expected to close H1 2024.
- Axonics offers SNM therapy for overactive bladder and fecal incontinence with Axonics R20 neurostimulator (20+ year battery).
- Deal expected to be immaterial to BSX adjusted EPS in 2024, accretive thereafter.
- Expands BSX urology portfolio into high-growth SNM adjacency, targeting ~30M OAB patients in US.

## SEC filing metadata
- accession: 0000885725-24-000003
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572524000003/0000885725-24-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572524000003/bsx-20240108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885725-24-000003
- JSON: https://secwatch.observer/filing/0000885725-24-000003.json
- Plain text: https://secwatch.observer/filing/0000885725-24-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.